{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T15:47:18Z","timestamp":1791388038610,"version":"4.3.3"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T00:00:00Z","timestamp":1710892800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T00:00:00Z","timestamp":1710892800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100023331","name":"Leo Pharma","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100023331","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The Investigator Global Assessment of Chronic Hand Eczema (IGA\u2013CHE) is a novel Clinician-Reported Outcome measure that allows investigators to assess cross-sectional CHE global disease severity using clinical characteristics of erythema, scaling, lichenification\/hyperkeratosis, vesiculation, oedema, and fissures as guidelines for overall severity assessment. This study aimed to evaluate the psychometric properties of the IGA\u2013CHE for use as an outcome measure in CHE clinical trials and clinical practice. Psychometric analyses were performed using data from a sample of 280 patients with moderate to severe CHE from a phase 3 trial of delgocitinib cream, pooled across treatment groups. Test\u2013retest reliability results were moderate to strong with kappa coefficients ranging from 0.63 to 0.76. Correlations with measures assessing related concepts were moderate or strong (range 0.65\u20130.72) and exceeded a priori hypotheses, providing evidence of convergent validity. Known-groups validity was supported by statistically significant differences between severity groups (&lt;\u20090.001). Within-group effect sizes were consistently larger for improved groups compared to stable groups, providing evidence of ability to detect change. Anchor-based analyses generated within-subject meaningful change estimates ranging from \u2013\u00a00.8 to \u2013\u00a02.3. A correlation weighted average suggested a single value of \u2013\u00a01.7 in change from baseline. These findings provide evidence the IGA\u2013CHE scale has strong reliability, construct validity, and ability to detect change, supporting its use as an endpoint in CHE clinical trials and clinical practice. Based on the evidence, 2-level changes in IGA\u2013CHE score are considered a conservative meaningful change threshold; however, findings also indicate 1-level change in IGA\u2013CHE scores reflects a clinically meaningful improvement for patients.<\/jats:p><jats:p><jats:italic>Clinical trial registration<\/jats:italic>: NCT04871711.<\/jats:p>","DOI":"10.1007\/s00403-024-02818-3","type":"journal-article","created":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T14:02:23Z","timestamp":1710943343000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Validation of the Investigator Global Assessment of Chronic Hand Eczema (IGA\u2013CHE): a new clinician reported outcome measure of CHE severity"],"prefix":"10.1007","volume":"316","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3686-7805","authenticated-orcid":false,"given":"Jonathan I.","family":"Silverberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7543-8299","authenticated-orcid":false,"given":"Tove","family":"Agner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2333-0896","authenticated-orcid":false,"given":"Keith","family":"Baranowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7351-8825","authenticated-orcid":false,"given":"Ursula","family":"Plohberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Thoning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0345-2523","authenticated-orcid":false,"given":"Rob","family":"Arbuckle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Grant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7115-0394","authenticated-orcid":false,"given":"George","family":"Skingley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5927-6587","authenticated-orcid":false,"given":"Robert","family":"Bissonnette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,20]]},"reference":[{"issue":"3","key":"2818_CR1","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1097\/der.0000000000000598","volume":"31","author":"S Capucci","year":"2020","unstructured":"Capucci S, Hahn-Pedersen J, Vilsb\u00f8ll A, Kragh N (2020) Impact of atopic dermatitis and chronic hand eczema on quality of life compared with other chronic diseases. Dermatitis 31(3):178\u2013184. https:\/\/doi.org\/10.1097\/der.0000000000000598","journal-title":"Dermatitis"},{"issue":"Suppl 1","key":"2818_CR2","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/jdv.16061","volume":"34","author":"T Agner","year":"2020","unstructured":"Agner T, Elsner P (2020) Hand eczema: epidemiology, prognosis and prevention. J Eur Acad Dermatol Venereol 34(Suppl 1):4\u201312. https:\/\/doi.org\/10.1111\/jdv.16061","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"2818_CR3","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/cod.14035","volume":"86","author":"JP Thyssen","year":"2022","unstructured":"Thyssen JP, Schuttelaar MLA, Alfonso JH, Andersen KE, Angelova-Fischer I, Arents BWM et al (2022) Guidelines for diagnosis, prevention, and treatment of hand eczema. Contact Dermatitis 86(5):357\u2013378. https:\/\/doi.org\/10.1111\/cod.14035","journal-title":"Contact Dermatitis"},{"key":"2818_CR4","unstructured":"FDA\/Center for Drug Evaluation and Research (2010) Draft guidance on pimecrolimus. Washington, DC"},{"key":"2818_CR5","unstructured":"FDA\/Center for Drug Evaluation and Research (2010) Draft guidance on calcipotriene. Washington, DC"},{"key":"2818_CR6","doi-asserted-by":"crossref","unstructured":"Silverberg J, Agner T, Baranowski K, Plohberger U, Thoning H, Arbuckle R et al (2023) Validation of the Investigator Global Assessment of Chronic Hand Eczema (IGA-CHE): a new clinician reported outcome measure [Poster]. EADV Congress","DOI":"10.1007\/s00403-024-02818-3"},{"key":"2818_CR7","unstructured":"FDA (2009) Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-reported-outcome-measures-use-medical-product-development-support-labeling-claims"},{"key":"2818_CR8","unstructured":"FDA (2022) Patient-Focused Drug Development: Selecting, Developing, or Modifying Fit-for-Purpose Clinical Outcome Assessments, Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders. 2022. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-focused-drug-development-selecting-developing-or-modifying-fit-purpose-clinical-outcome"},{"key":"2818_CR9","unstructured":"FDA (2023) Patient-Focused Drug Development: Incorporating Clinical Outcome Assessments Into Endpoints For Regulatory Decision-Making: Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-focused-drug-development-incorporating-clinical-outcome-assessments-endpoints-regulatory"},{"key":"2818_CR10","unstructured":"FDA (2020) Patient-Focused Drug Development: Collecting Comprehensive and Representative Input: Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-focused-drug-development-collecting-comprehensive-and-representative-input"},{"key":"2818_CR11","unstructured":"EMA (2005) Reflection paper on the regulatory guidance for the use of health-quality of life (HRQL) measures in the evaluation of medicinal products. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/reflection-paper-regulatory-guidance-use-health-related-quality-life-hrql-measures-evaluation_en.pdf"},{"issue":"1","key":"2818_CR12","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1111\/bjd.21037","volume":"187","author":"M Worm","year":"2022","unstructured":"Worm M, Thyssen JP, Schliemann S, Bauer A, Shi VY, Ehst B et al (2022) The pan-JAK inhibitor delgocitinib in a cream formulation demonstrates dose response in chronic hand eczema in a 16-week randomized phase IIb trial. Br J Dermatol 187(1):42\u201351. https:\/\/doi.org\/10.1111\/bjd.21037","journal-title":"Br J Dermatol"},{"key":"2818_CR13","doi-asserted-by":"crossref","unstructured":"Molin S, Seiding Larsen L, Joensson P, Oesterdal ML, Arbuckle R, Grant L et al (2023) Development and psychometric validation of a new patient-reported outcome measure to assess the signs and symptoms of chronic hand eczema (CHE): the Hand Eczema Symptom Diary (HESD). EADV Congress","DOI":"10.1007\/s13555-024-01114-2"},{"issue":"2","key":"2818_CR14","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1111\/j.1365-2133.2004.06305.x","volume":"152","author":"E Held","year":"2005","unstructured":"Held E, Skoet R, Johansen J, Agner T (2005) The hand eczema severity index (HECSI): a scoring system for clinical assessment of hand eczema. A study of inter-and intraobserver reliability. Br J Dermatol 152(2):302\u2013307","journal-title":"Br J Dermatol"},{"key":"2818_CR15","unstructured":"HECSI [Available from: https:\/\/hecsiscore.com\/"},{"key":"2818_CR16","volume-title":"Statistical methods for rates and proportions","author":"JL Fleiss","year":"2013","unstructured":"Fleiss JL, Levin B, Paik MC (2013) Statistical methods for rates and proportions. Wiley"},{"key":"2818_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m1714","volume":"369","author":"T Devji","year":"2020","unstructured":"Devji T, Carrasco-Labra A, Qasim A, Phillips M, Johnston BC, Devasenapathy N et al (2020) Evaluating the credibility of anchor based estimates of minimal important differences for patient reported outcomes: instrument development and reliability study. BMJ 369:m1714. https:\/\/doi.org\/10.1136\/bmj.m1714","journal-title":"BMJ"},{"key":"2818_CR18","volume-title":"Applied statistics for the behavioral sciences","author":"DE Hinkle","year":"2003","unstructured":"Hinkle DE, Wiersma W, Jurs SG (2003) Applied statistics for the behavioral sciences. Houghton Mifflin, Boston, Mass, [London]"},{"issue":"2","key":"2818_CR19","doi-asserted-by":"publisher","first-page":"107","DOI":"10.2307\/1164588","volume":"6","author":"LV Hedges","year":"1981","unstructured":"Hedges LV (1981) Distribution theory for glass\u2019s estimator of effect size and related estimators. J Educ Stat 6(2):107\u2013128. https:\/\/doi.org\/10.2307\/1164588","journal-title":"J Educ Stat"},{"key":"2818_CR20","doi-asserted-by":"publisher","DOI":"10.4324\/9780203771587","volume-title":"Statistical power analysis for the behavioral sciences","author":"J Cohen","year":"2013","unstructured":"Cohen J (2013) Statistical power analysis for the behavioral sciences. Academic press"},{"issue":"3 Suppl","key":"2818_CR21","doi-asserted-by":"publisher","first-page":"S178","DOI":"10.1097\/00005650-198903001-00015","volume":"27","author":"LE Kazis","year":"1989","unstructured":"Kazis LE, Anderson JJ, Meenan RF (1989) Effect sizes for interpreting changes in health status. Med Care 27(3 Suppl):S178\u2013S189. https:\/\/doi.org\/10.1097\/00005650-198903001-00015","journal-title":"Med Care"},{"issue":"2","key":"2818_CR22","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.jclinepi.2007.03.012","volume":"61","author":"D Revicki","year":"2008","unstructured":"Revicki D, Hays RD, Cella D, Sloan J (2008) Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. J Clin Epidemiol 61(2):102\u2013109. https:\/\/doi.org\/10.1016\/j.jclinepi.2007.03.012","journal-title":"J Clin Epidemiol"},{"issue":"10","key":"2818_CR23","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1007\/s11136-021-02957-4","volume":"30","author":"A Trigg","year":"2021","unstructured":"Trigg A, Griffiths P (2021) Triangulation of multiple meaningful change thresholds for patient-reported outcome scores. Qual Life Res 30(10):2755\u20132764. https:\/\/doi.org\/10.1007\/s11136-021-02957-4","journal-title":"Qual Life Res"},{"issue":"5","key":"2818_CR24","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1097\/01.Mlr.0000062554.74615.4c","volume":"41","author":"GR Norman","year":"2003","unstructured":"Norman GR, Sloan JA, Wyrwich KW (2003) Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care 41(5):582\u2013592. https:\/\/doi.org\/10.1097\/01.Mlr.0000062554.74615.4c","journal-title":"Med Care"},{"key":"2818_CR25","first-page":"386","volume-title":"Outcomes assessment in cancer: measures, methods and applications","author":"D Osoba","year":"2005","unstructured":"Osoba D (2005) The clinical value and meaning of health-related quality-of-life outcomes in oncology. In: Gotay C, Snyder C, Lipscomb J (eds) Outcomes assessment in cancer: measures, methods and applications. Cambridge University Press, Cambridge, pp 386\u2013405"},{"issue":"4","key":"2818_CR26","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1111\/j.1365-2133.2008.08487.x","volume":"158","author":"T Ruzicka","year":"2008","unstructured":"Ruzicka T, Lynde CW, Jemec GB, Diepgen T, Berth-Jones J, Coenraads PJ et al (2008) Efficacy and safety of oral alitretinoin (9-cis retinoic acid) in patients with severe chronic hand eczema refractory to topical corticosteroids: results of a randomized, double-blind, placebo-controlled, multicentre trial. Br J Dermatol 158(4):808\u2013817. https:\/\/doi.org\/10.1111\/j.1365-2133.2008.08487.x","journal-title":"Br J Dermatol"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-02818-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-024-02818-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-02818-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T13:04:42Z","timestamp":1712667882000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-024-02818-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,20]]},"references-count":26,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,5]]}},"alternative-id":["2818"],"URL":"https:\/\/doi.org\/10.1007\/s00403-024-02818-3","relation":{},"ISSN":["1432-069X"],"issn-type":[{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,20]]},"assertion":[{"value":"20 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"JS: has received honoraria as a consultant and\/or advisory board member and\/or speaker and\/or received grants from AbbVie, Alamar, Aldena, Aobiome, Arcutis, Arena, Asana, Aslan, BioMX, Biosion, Bodewell, Boehringer-Ingelheim, Bristell-Myers Sqibb, Cara, Castle Biosciences, Celgene, Connect Biopharma, Corevitas, Dermavant, Dermtech, Eli Lilly, Galderma, GlaxoSmithKline, Incyte, Kiniksa, LEO Pharma A\/S, Novartis, Optum, Pfizer, RAPT, Recludix, Regeneron, Sanofi-Genzyme, Shaperon, TARGET-RWE, Union.. TA: has given lectures, participated in clinical studies, or been on advisory boards for Sanofi, LEO Pharma, Pfizer, Eli Lilly, Galderma, and AbbVie. KB, UP, HT: are employees of LEO Pharma A\/S, Ballerup, Denmark. RA, LG, GS: are employees of Adelphi Values, Patient-Centered Outcomes, Cheshire UK, and Adelphi Values was contracted by LEO Pharma to support them in performing the psychometric analyses. RB: is an advisory board member, consultant, speaker and\/or investigator for and receives honoraria and\/or grants from AbbVie, Arcutis, Arena Pharma, Asana BioSciences, Bellus Health, Boehringer-Ingelheim, CARA, Dermavant, Eli Lilly, EMD Serono, Galderma, Incyte, Kiniksa, Kyowa Kirin, LEO Pharma, Novan, Pfizer, Ralexar, RAPT, Regeneron, Sanofi Genzyme, and Sienna. He is also an employee and shareholder of Innovaderm Research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The trial was conducted in accordance with the consensus of ethical principles from internal guidelines including the Declaration of Helsinki, Council for Internal Organization of Medical Sciences (CIOMS) International Ethical Guidelines, International Council of Harmonization Good Clinical Practice (ICH GCP) Guideline, EU General Data Regulation 2016\/679 of 27 April 2016 and in compliance with the approved protocol and applicable laws and regulations. All procedures involving study participants were approved by the institutional review board or independent ethics committees at all investigational sites.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent to participate in the trial and publication was obtained from all subjects.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"110"}}